Treatment with a nucleoside analogue and subsequent viral decline has shown to partially restore immune hyporesponsiveness in chronic hepatitis B patients. Recent pilot studies investigating whether the effect of lowering viral load with nucleoside analogue therapy prior to the initiation of peginterferon results in higher sustained off-treatment responses showed contradictory findings. The aim of this study is to investigate sustained off-treatment response to peginterferon alfa-2b in chronic HBeAg-positive hepatitis B patients who are pretreated with nucleos(t)ide analogues, thereby lowering viral load
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
82
Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
Ruijin Hospital "Jiaolong University"
Shanghai, China
Public Health Center "Fu Dan University"
Shanghai, China
Zhong Shan Hospital "Fu Dan University"
Shanghai, China
Erasmus MC, University Medical Center
Rotterdam, Netherlands
Sustained response
Sustained response to therapy, defined as the combined presence of HBeAg seroconversion and HBV DNA \< 200 IU/mL
Time frame: at week 72
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.